💊 The "hidden skills" of tirzepatide: Besides weight loss, what else can it improve

Japan's Mounjaro: Tirzepatide Weight-Loss Injection

Hong Kong weight loss injection | Hong Kong skinny jab | Hong Kong Saxenda

GIP / GLP-1 receptor agonist | Type 2 diabetes | Glucose-lowering and blood sugar control | Lipid-lowering and weight loss | Insulin adjustment

In addition to demonstrating significant efficacy in weight management, tixiparib effectively improves blood glucose control and related metabolic markers in patients with diabetes, further enhancing their overall health. The multiple benefits of this medication have made it an increasingly prominent option in treatment regimens.

Many people areTirzepatideMany people still think of it as just a “weight-loss shot.” It’s true that its weight-loss effects are indeed remarkable—an average weight loss of over 20% over 72 weeks. But if you view it merely as a weight-loss drug, you’re really underestimating it.

Over the past year, a series of groundbreaking studies has revealed the “hidden identity” of texipetide: it is not only a weight-loss tool, but also aSystemic Metabolic Regulator. Today, let’s take a look at the wide range of health benefits it offers beyond weight loss.

Comprehensive metabolic protection of Tirzepatide / Mounjaro

❤️ 1. Heart Protection: Risk of Hospitalization for Heart Failure Drops by 58%

A 2025 study published in JAMA showed that, compared with placebo, tirzepatide reduced the risk of heart failure hospitalization or all-cause death in patients with heart failure with preserved ejection fraction (HFpEF)Decreased by 58%and this protective effect holds true across patients of all ages and genders.

A 2026 meta-analysis also confirmed that tirzepatide is associated with a reduced risk of major adverse cardiovascular events (MACE) and all-cause mortality. What is even more noteworthy is that its effects aredose-dependent—For every 1 mg increase in dose, the risk of MACE is further reduced by 2.81 TP3T; greater benefits are observed with higher doses.

Furthermore, regardless of whether patients have concomitant type 2 diabetes, tirzepatide consistently improves heart failure symptoms and function, demonstrating cardioprotective performance across all populations.

😴 2. Treating snoring: The world's first approved OSA drug

In December 2024, the US FDA officially approved tirzepatide for the treatment ofmoderate-to-severe obstructive sleep apnea (OSA), becoming the world's first approved drug to treat OSA.

SURMOUNT-OSA study data showed that among patients not receiving PAP therapy, the tirzepatide group AHI index (apnea events/hour)Decreased by an average of 25.3 times/hour(while the placebo group saw a reduction of only 5.3 events/hour); whereas the group of patients receiving PAP treatment showed a more significant effect, with the AHI index decreasing by 29.3 events/hour.

In addition to reducing body weight from 18% to 20%, the mechanism also involves regulating fat distribution and autonomic nervous system function, thereby improving sleep-related breathing patterns, lowering blood pressure, and reducing inflammatory markers.

🫁 3. Liver Protection: MASH has a response rate as high as 62%

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, is one of the most common liver diseases. The SYNERGY-NASH study published in the NEJM in 2025 brought exciting results.

In MASH patients with moderate or severe liver fibrosis,Patients in the 15 mg tesipepetide group of the 62% trial achieved MASH remission without worsening fibrosis(Only 10% were in the placebo group.) At the same time, 51% to 55% patients showed improvement of at least one fibrosis stage.

A large-scale meta-analysis conducted in 2026 also confirmed that the relative risk (RR) of tezipatide for MASH remission was as high as 5.33, and patients’ ALT and AST levels also decreased significantly(with long-term users showing a reduction of approximately 13% to 20%).

🩸 4. Lowers blood lipids + Kidney protection dual effect in one

Multiple studies have confirmed that tirzepatide can simultaneously improve blood lipids and renal function while promoting weight loss:

• Improvement in blood lipids and blood pressure: Triglycerides decreased by an average of 19.61 TP3T, total cholesterol decreased by 18.71 TP3T, “bad cholesterol” (LDL-C) decreased by 30.51 TP3T, and systolic blood pressure decreased by an average of approximately 5.8 mmHg.
• Kidney protection: Real-world studies show that long-term use (>1 year) can increase the estimated glomerular filtration rate (eGFR) by 3.2%,a 6.6% decrease in serum creatinine, and a 7.8% decrease in blood urea nitrogen, effectively slowing the decline in eGFR.

⚠️ Summary: Cross-disciplinary all-around metabolic protector

Tirzepatide is rapidly evolving from a "weight-loss drug" intocomprehensive metabolic protectantIt not only helps with healthy weight loss, but also demonstrates exceptional comprehensive benefits in heart protection, treatment of sleep apnea, improvement of fatty liver, lowering of blood lipids, and kidney protection, and is becoming an important benchmark for future metabolic disease management.